Microarchitecture, Bone Strength and Fracture Risk in Long-term Type 1 Diabetes (BOLD-1)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Basel Stadt
-
Basel, Basel Stadt, Switzerland, 4031
- Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- women and men with longstanding type 1 diabetes (age 40-80 years, BMI 18-37 kg/m2 and age- and sex matched non-diabetic controls
- presence of type 1 diabetes for at least 25 years (defined by history of Insulin treatment)
Exclusion Criteria:
- Patients unable to give written informed consent, e.g. with severe dementia or patients not understanding German (or other local language)
- Any medical or psychiatric condition which would preclude the participant from adhering to the protocol
- Idiopathic or premenopausal osteoporosis or coexisting metabolic bone disease (e.g. Paget´s disease, primary hyperparathyroidism)
- Previous treatment with osteoporosis medication (bisphosphonates, denosumab) or intake of medications that are known to affect bone metabolism (e.g. steroids, anticonvulsants) within 6 months prior to enrollment
- Patients with medical conditions known to affect bone health ( e.g. metastatic bone disease, celiac disease, inflammatory bone disease, hypogonadism, thyrotoxicosis, hypercortisolism, chronic kidney disease stage IV and V (KDIGO), liver dysfunction (serum aspartate amino transferase (ASAT) >3 times the upper limit of normal)
- Inability to keep the extremities still for a few minutes of an HR-pQCT examination (e.g. Parkinson disease, spastic syndrome)
- Pregnant or breastfeeding women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Diagnostic
The investigators will examine all participants in the same way by performing biochemical tests, clinical tests, osteodensitometry, HRQCT and HRpQCT measurements.
|
The investigators will perform blood tests in every participant.
The investigators will perform an osteodensitometry in every participant.
Other Names:
The investigators perform the following clinical tests: vibration threshold test, monofilament test, chair rise test and timed up and go test in every participant.
The investigators will perform HR-QCT measurements of the proximal femur and tibia in every participant.
The investigators will perform HR-pQCT measurements of the distal radius and distal tibia in every participant.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
volumetric bone mineral density in mg hydroxyapatite (HA)/ccm
Time Frame: through study completion, an average of 6 months
|
measured by HR-pQCT at the distal radius and tibia
|
through study completion, an average of 6 months
|
|
cortical porosity in %
Time Frame: through study completion, an average of 6 months
|
measured by HR-pQCT at the distal radius and tibia
|
through study completion, an average of 6 months
|
|
bone stiffness in kilonewton (kN)/mm
Time Frame: through study completion, an average of 6 months
|
a measure of bone strength, measured by HR-pQCT at the distal radius and tibia
|
through study completion, an average of 6 months
|
|
failure load in kN
Time Frame: through study completion, an average of 6 months
|
a measure of bone strength, measured by HR-pQCT at the distal radius and tibia
|
through study completion, an average of 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
areal bone mineral density of the spine in g/cm2
Time Frame: through study completion, an average of 6 months
|
measured by osteodensitometry (DXA)
|
through study completion, an average of 6 months
|
|
areal bone mineral density of the proximal femur in g/cm2
Time Frame: through study completion, an average of 6 months
|
measured by osteodensitometry
|
through study completion, an average of 6 months
|
|
areal bone mineral density of the distal radius in g/cm2
Time Frame: through study completion, an average of 6 months
|
measured by osteodensitometry
|
through study completion, an average of 6 months
|
|
trabecular bone score of the spine
Time Frame: through study completion, an average of 6 months
|
a measure of bone texture, measured by osteodensitometry
|
through study completion, an average of 6 months
|
|
cortical thickness at the mid tibia in cm
Time Frame: through study completion, an average of 6 months
|
the cortical thickness will be measured by pulse-echo ultrasound and high resolution quantitative computed tomography (HR-QCT)
|
through study completion, an average of 6 months
|
|
density weighed cortical thickness at the mid tibia in cm
Time Frame: through study completion, an average of 6 months
|
the density weighed cortical thickness will be measured by pulse-echo ultrasound and HR- QCT
|
through study completion, an average of 6 months
|
|
bone marrow adiposity in mg/cm3
Time Frame: through study completion, an average of 6 months
|
measured by HR-pQCT
|
through study completion, an average of 6 months
|
|
measurement of serum carboxy-terminal collagen crosslinks (CTX) in pg/ml
Time Frame: through study completion, an average of 6 months
|
biochemical marker of bone resorption
|
through study completion, an average of 6 months
|
|
measurement of serum n-terminal procollagen type 1 (P1NP) in mcg/l
Time Frame: through study completion, an average of 6 months
|
biochemical marker of bone formation
|
through study completion, an average of 6 months
|
|
measurement of serum pentosidine in pmol/m
Time Frame: through study completion, an average of 6 months
|
biochemical marker associated with bone fragility
|
through study completion, an average of 6 months
|
|
measurement of serum carboxymethyl-lysine (CML) in pmol/ml
Time Frame: through study completion, an average of 6 months
|
biochemical marker associated with bone fragility
|
through study completion, an average of 6 months
|
|
measurement of serum insulin in mU/ml
Time Frame: through study completion, an average of 6 months
|
biochemical marker associated with bone fragility
|
through study completion, an average of 6 months
|
|
measurement of serum sclerostin in pg/ml
Time Frame: through study completion, an average of 6 months
|
biochemical marker associated with bone fragility
|
through study completion, an average of 6 months
|
|
measurement of serum adiponectin in ng/ml
Time Frame: through study completion, an average of 6 months
|
biochemical marker associated with bone fragility
|
through study completion, an average of 6 months
|
|
measurement of serum insulin like growth factor -1 (IGF1) in nM
Time Frame: through study completion, an average of 6 months
|
biochemical marker associated with bone fragility
|
through study completion, an average of 6 months
|
|
measurement of serum ultrasensitive c-reactive protein (usCRP) in mg/l
Time Frame: through study completion, an average of 6 months
|
biochemical marker associated with bone fragility
|
through study completion, an average of 6 months
|
|
measurement of serum interleukin 6 (IL6) in pg/ml
Time Frame: through study completion, an average of 6 months
|
biochemical marker associated with bone fragility
|
through study completion, an average of 6 months
|
|
measurement of serum periostin in ng/ml
Time Frame: through study completion, an average of 6 months
|
biochemical marker associated with bone fragility
|
through study completion, an average of 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Christian Meier, Prof., University Hospital, Basel, Switzerland
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EKNZ 2018-01517
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.